Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L, Seferian A, Phelep A, Rippert P, Mathieu ML, Cances C, de Lattre C, Durigneux J, Gousse G, Vincent-Genod D, Ribault S, Gómez García de la Banda M, Quijano-Roy S, Sarret C, Servais L, Vuillerot C. Le Goff L, et al. Neurol Sci. 2023 Mar;44(3):1139. doi: 10.1007/s10072-022-06522-w. Neurol Sci. 2023. PMID: 36418612 Free article. No abstract available.
Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.
Armengol VD, Darras BT, Abulaban AA, Alshehri A, Barisic N, Ben-Omran T, Bernert G, Castiglioni C, Chien YH, Farrar MA, Kandawasvika G, Khadilkar S, Mah J, Marini-Bettolo C, Osredkar D, Pfeffer G, Piazzon FB, Pitarch Castellano I, Quijano-Roy S, Saito K, Shin JH, Vázquez-Costa JF, Walter MC, Wanigasinghe J, Xiong H, Griggs RC, Roy B. Armengol VD, et al. Neurol Clin Pract. 2024 Feb;14(1):e200224. doi: 10.1212/CPJ.0000000000200224. Epub 2023 Dec 15. Neurol Clin Pract. 2024. PMID: 38107546
Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L, Seferian A, Phelep A, Rippert P, Mathieu ML, Cances C, de Lattre C, Durigneux J, Gousse G, Vincent-Genod D, Ribault S, Gomez Garcia de la Banda M, Quijano-Roy S, Sarret C, Servais L, Vuillerot C. Le Goff L, et al. Neurol Sci. 2023 Jan;44(1):329-337. doi: 10.1007/s10072-022-06403-2. Epub 2022 Sep 29. Neurol Sci. 2023. PMID: 36175810
A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy.
Barrois R, Barnerias C, Deladrière E, Leloup-Germa V, Tervil B, Audic F, Boulay C, Cances C, Cintas P, Davion JB, Espil-Taris C, Manel V, Pereon Y, Piarroux J, Quijano Roy S, Vuillerot C, Walther-Louvier U, Desguerre I, Gitiaux C. Barrois R, et al. Neuromuscul Disord. 2023 Apr;33(4):309-314. doi: 10.1016/j.nmd.2023.02.004. Epub 2023 Feb 11. Neuromuscul Disord. 2023. PMID: 36881951
Complex SMN Hybrids Detected in a Cohort of 31 Patients With Spinal Muscular Atrophy.
Costa-Roger M, Blasco-Pérez L, Gerin L, Codina-Solà M, Leno-Colorado J, Gómez-García De la Banda M, Garcia-Uzquiano R, Saugier-Veber P, Drunat S, Quijano-Roy S, Tizzano EF. Costa-Roger M, et al. Among authors: quijano roy s. Neurol Genet. 2024 Jul 16;10(4):e200175. doi: 10.1212/NXG.0000000000200175. eCollection 2024 Aug. Neurol Genet. 2024. PMID: 39035824 Free PMC article.
Characterization of cardiac involvement in children with LMNA-related muscular dystrophy.
Cesar S, Campuzano O, Cruzalegui J, Fiol V, Moll I, Martínez-Barrios E, Zschaeck I, Natera-de Benito D, Ortez C, Carrera L, Expósito J, Berrueco R, Bautista-Rodriguez C, Dabaj I, Gómez García-de-la-Banda M, Quijano-Roy S, Brugada J, Nascimento A, Sarquella-Brugada G. Cesar S, et al. Front Cell Dev Biol. 2023 Mar 10;11:1142937. doi: 10.3389/fcell.2023.1142937. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36968203 Free PMC article.
Parents' dilemma: A therapeutic decision for children with spinal muscular atrophy (SMA) type 1.
Boursange S, Araneda M, Stalens C, Desguerre I, Barnerias C, Nougues MC, Isapof A, Quijano-Roy S, Blu Genestine N, Ouillade L, Martinez Jalilie M, Castiglioni C, Boespflug-Tanguy O, Gargiulo M; SMAPAR Study Group. Boursange S, et al. Front Pediatr. 2022 Dec 21;10:1062390. doi: 10.3389/fped.2022.1062390. eCollection 2022. Front Pediatr. 2022. PMID: 36619514 Free PMC article.
Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation.
Beaufils M, Melka M, Brocard J, Benoit C, Debbah N, Mamchaoui K, Romero NB, Dalmas-Laurent AF, Quijano-Roy S, Fauré J, Rendu J, Marty I. Beaufils M, et al. Among authors: quijano roy s. Mol Ther Nucleic Acids. 2024 Jun 17;35(3):102259. doi: 10.1016/j.omtn.2024.102259. eCollection 2024 Sep 10. Mol Ther Nucleic Acids. 2024. PMID: 39071953 Free PMC article.
157 results